ClinicalTrials.gg
CompletedNCT03304418RROPEUpdated Apr 30, 2025Results posted

Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone

A Phase 2 interventional study of Radium Ra 223 Dichloride and Radiation in Prostate Cancer Metastatic to Bone, sponsored by University of Utah. Completed at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-30.

Sponsored by University of Utah · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 25 studies testing radium Ra 223 dichloride in Prostatic Neoplasms — none open to participants now, 1 under way, none of them phase 3. radium Ra 223 dichloride · Prostatic Neoplasms.

Enrollment
21st of 25
20 · median 49
Started
2018
with 1 other
Phase 2
13 of 25
none open now
Registered
23rd of 25
by date
Lead sponsor
2 of 25
University of Utah

Among the 25 studies testing radium Ra 223 dichloride in Prostatic Neoplasms, this one is the 21st largest by enrollment, is one of 2 that started in 2018, is one of 13 in phase 2, and was the 23rd registered.

Prostatic Neoplasms

7,055 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

None of the 25 studies testing radium Ra 223 dichloride in Prostatic Neoplasms is open now. The open studies under Prostatic Neoplasms, anywhere →

About radium Ra 223 dichloride

radium Ra 223 dichloride: first FDA approval 2013 (XOFIGO), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 25 studies testing radium Ra 223 dichloride in Prostatic Neoplasms as a file.
02

Study summary

This is a phase IIa, open label, single arm, and prospective study of hormone therapy-naïve men with oligometastatic prostate cancer to the bone. The study will test if treating the primary tumor sites and 5 or fewer sites of bone-only metastasis with external beam radiation with concomitant systemic Radium-223 will reduce the utilization of androgen deprivation therapy, improve QOL and improve OS over a the comparator cohort of SWOG intermittent ADT historic cohort.

03

Conditions studied

  • Prostate Cancer Metastatic to Bone

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Asymptomatic or symptomatic hormone naïve men with testosterone levels ≥100 ng/dL with previously treated localized prostate cancer who now have rising PSA's and five or fewer bone .
  • Subjects who have been previously treated with definitive and/or /salvage radiotherapy to the primary site and/or regional lymph nodes with concurrent ADT are allowed if the last hormone therapy delivered > 6 months prior. Subjects who have had more than 30 days and fewer than 45 days of bicalutamide monotherapy for any reason within the 6 months prior to enrollment are eligible for the study, providing they have been off of the drug for at least 30 days prior to enrollment. Subjects who have had fewer than 30 days of bicalutamide are eligible for the study, as long as they discontinue the drug at least 5 days prior to the first study treatment.
  • Histologic confirmation of Prostate Adenocarcinoma diagnosis.
  • Age ≥ 18 years.
  • of at least 2 years.
  • Acceptable hematology and serum biochemistry screening values:

    • White Blood Cell Count (WBC) ≥ 3,000/mm3
    • (ANC) ≥ 1,500/mm3
    • (PLT) count ≥ 100,000/mm3
    • (HGB) ≥ 10 g/dl
    • Total level ≤ 1.5 x institutional (ULN)
    • (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN
    • Creatinine ≤ 1.5 x ULN
    • Albumin > 2.5 mg/dL
  • Willing and able to comply with the protocol, including follow-up visits and examinations.
  • Performance Score >60 or equivalent.
  • Radiographic confirmation of oligometastatic diagnosis via Bone Scan validated by either CT scan or MRI or PET/CT with Fluciclovine within the past 90 days.
  • Subjects who have not had surgical removal of their prostate and have a partner of child bearing potential must agree to use condoms beginning at the signing of the ICF until at least 6 months after the last dose of study drug. Because of the potential side effect on spermatogenesis associated with radiation, female partners of must agree to use a highly effective method during and for 6 months after completing treatment
  • Able to provide and willing to sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion criteria

Exclusion Criteria:

  • Men with known brain or visceral (except regional lymph nodes as defined by section 5.2.5) defined by CT or MRI Imaging of the abdomen or pelvis.
  • Men who have had LHRH agonist or antagonist hormone therapy in the prior six months.
  • Men with >5 bony metastases.
  • Men with baseline serum Testosterone \<100 ng/dL.
  • Men with new or progressing lymphadenopathy clearly consistent with prostate metastasis on imaging or proven by pathologic at any time three months or later following their initial definitive therapy.
  • Prior or concurrent invasive (except non-melanomatous skin cancer) or lymphomatous/hematogenous malignancy unless continually disease free for a minimum of 3 years. All patients with in situ carcinoma are eligible for this study (for example, carcinoma in situ of the oral cavity is eligible) except patients with carcinoma of the bladder (including in situ bladder cancer or superficial bladder cancer).
  • Use of finasteride within 30 days prior to therapy PSA should not be obtained prior to 30 days after stopping finasteride.
  • Use of dutasteride within 90 days prior to therapy. PSA should not be obtained prior to 90 days after stopping dutasteride.
  • Previous or concurrent cytotoxic chemotherapy for prostate cancer.
  • Received systemic therapy with radionuclides (e.g., strontium-89, samarium-153, rhenium-186, or rhenium-188, or Radium Ra 223 dichloride) for the treatment of bony metastases.
  • Men who will receive radical prostatectomy to the primary site.
  • Imminent spinal cord compression based on clinical findings and/or magnetic resonance imaging (MRI). Spinal Cord compression will be defined as 360 degree circumferential obliteration of T2 cerebrospinal fluid signal around the spinal cord. Treatment should be completed for spinal cord compression.
  • Severe, active co-morbidity, defined as follows:

    • Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
    • Transmural myocardial infarction within the last 6 months
    • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
    • exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
    • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol. (Patients on Coumadin or other blood thinning agents are eligible for this study.)
    • Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly .
  • Cardiac failure (NYHA) III or IV Crohn's disease or ulcerative colitis.
  • Bone marrow dysplasia.
  • Fecal incontinence.
  • Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Radium Ra 223 dichloride and radiation, all patients

    Drug: Radium Ra 223 Dichloride · Radiation: Radiation

Interventions

  • Radium Ra 223 dichloride will be delivered intravenously at 55 kBq/kg (1.49 mCi)/kg (+/- 10% total dose) for a total of six cycles. 1 cycle= 28 days. The first cycle will commence at study enrollment, then cycles 2-6 will commence after the completion of radiotherapies at 4 week intervals

    Also known as: Xofigo

  • RadiationRadiation

    All external beam radiations oligometastatic sites will commence after cycle 1 of Radium-223 but prior to cycle 2 of Radium-223. All subjects will receive Stereotactic body or hypofractionated radiation to sites of bone disease seen on imaging studies. Patients will have the primary tumor sites and 5 or fewer sites of bone-only metastasis treated with external beam radiation. Any of the following regimens are considered ablative, acceptable and are biologically equivalent to 60Gy EQD2: * Single fraction: 16 Gy total at 16 Gy per fraction (SBRT) * Three fractions: 24 Gy total at 8 Gy per fraction (SBRT) * Five fractions: 30 Gy total at 6Gy per fraction (SBRT).When using five fractions, can reduce to 25 Gy total at 5 Gy per fraction (SBRT) or to a minimum of 20 Gy total at 4 Gy per fraction (SBRT), per treating investigator. * Six fractions: 32.4 Gy total at 5.4Gy per fraction (Hypofractionated)

06

What researchers measure

Primary outcomes

  1. Count of Participants Requiring Androgen Deprivation Therapy (ADT) Use at 15 Months

    To determine if 20% of ADT naïve men treated with concurrent EBRT and Radium-223 will not require ADT for progression by 15 months.

    Time frame: 15 months

Secondary outcomes

  1. Median Time From Start of Study Therapy to Start of ADT

    Determine the hormone-therapy free survival time for men treated with concurrent EBRT and Radium-223 and determine if it is a 30% risk reduction over the SWOG intermittent ADT historic cohort

    Time frame: 2 years

  2. Mean Expanded Prostate Inventory Composite (EPIC) Scores at End of Treatment

    To evaluate health related quality of life (QOL) as scored by the 50 item Expanded Prostate Inventory Composite (EPIC) EPIC urinary, bowel, sexual and hormonal domains. EPIC assesses the disease-specific aspects of prostate cancer and its therapies and comprises four summary domains (Urinary, Bowel, Sexual and Hormonal). Response options for each EPIC item form a Likert scale, and multi-item scale scores are transformed linearly to a 0-100 scale, with higher scores representing better health-related quality of life.

    Time frame: 6 months

  3. Mean PROMIS-29 Scores at End of Treatment

    To evaluate health related quality of life (QOL). The PROMIS-29 (Patient-Reported Outcomes Measurement Information System) will be used to assess general function and well-being. The raw score for each PROMIS instrument is converted to a T-score on a scale of 0-100. For most PROMIS instruments, a score of 50 is the average for the United States general population with a standard deviation of 10. A higher PROMIS T score represents more of the concept being measured. For negatively worded concepts like Anxiety, a T score of 60 is one SD worse than average. By comparison, an Anxiety T score of 40 is one SD better than average. However, for positively worded concepts like Physical Function Mobility, a T score of 60 is one SD better than average while a T score of 40 is one SD worse than average.

    Time frame: 6 months

  4. Evaluate Time to First Skeletal Related Event (SRE)

    Documentation of complications associated with bone metastases and may include (but not limited to) fractures, spinal cord compression, bone pain, and hypercalcemia.

    Time frame: 2 years

  5. Evaluate the PSA Doubling Time

    This outcome measure will report the mean time elapsed from baseline PSA to PSA to double in value. Participants were followed for 24 months from the initiation of study treatment. PSA doubling time was censored at 24 months.

    Time frame: 2 years, assessed at every visit in that time period

  6. Evaluate Overall Surival

    This outcome measure will report the overall survival at 2 years. Patients were followed for survival for two years after study enrollment. Patients who refused follow-up were censored at their off-study date.

    Time frame: 2 years after study enrollment

07

Results

Posted Jan 30, 2024

Participant flow

Participant flow — Overall Study
MilestoneRadium Ra 223 Dichloride and Radiation, All Patients
Started20
Completed20
Not completed0

Outcome measures

PrimaryCount of Participants Requiring Androgen Deprivation Therapy (ADT) Use at 15 Months

To determine if 20% of ADT naïve men treated with concurrent EBRT and Radium-223 will not require ADT for progression by 15 months.

Time frame:
15 months
Reported as:
Count of participants · Participants
Count of Participants Requiring Androgen Deprivation Therapy (ADT) Use at 15 Months
ParticipantsRadium Ra 223 Dichloride and Radiation, All Patients
Count of Participants Requiring Androgen Deprivation Therapy (ADT) Use at 15 Months10
SecondaryMedian Time From Start of Study Therapy to Start of ADT

Determine the hormone-therapy free survival time for men treated with concurrent EBRT and Radium-223 and determine if it is a 30% risk reduction over the SWOG intermittent ADT historic cohort

Time frame:
2 years
Reported as:
Median · Days
Median Time From Start of Study Therapy to Start of ADT
DaysRadium Ra 223 Dichloride and Radiation, All Patients
Median Time From Start of Study Therapy to Start of ADT260 ± 200.2
SecondaryMean Expanded Prostate Inventory Composite (EPIC) Scores at End of Treatment

To evaluate health related quality of life (QOL) as scored by the 50 item Expanded Prostate Inventory Composite (EPIC) EPIC urinary, bowel, sexual and hormonal domains. EPIC assesses the disease-specific aspects of prostate cancer and its therapies and comprises four summary domains (Urinary, Bowel, Sexual and Hormonal). Response options for each EPIC item form a Likert scale, and multi-item scale scores are transformed linearly to a 0-100 scale, with higher scores representing better health-related quality of life.

Time frame:
6 months
Reported as:
Mean · score on a scale
Mean Expanded Prostate Inventory Composite (EPIC) Scores at End of Treatment
score on a scaleRadium Ra 223 Dichloride and Radiation, All Patients
Urinary Summary Score74.1 ± 17.8
Bowel Summary Score89.1 ± 10.9
Sexual Summary Score12.4 ± 9.8
Hormonal Summary Score81.9 ± 17.5
SecondaryMean PROMIS-29 Scores at End of Treatment

To evaluate health related quality of life (QOL). The PROMIS-29 (Patient-Reported Outcomes Measurement Information System) will be used to assess general function and well-being. The raw score for each PROMIS instrument is converted to a T-score on a scale of 0-100. For most PROMIS instruments, a score of 50 is the average for the United States general population with a standard deviation of 10. A higher PROMIS T score represents more of the concept being measured. For negatively worded concepts like Anxiety, a T score of 60 is one SD worse than average. By comparison, an Anxiety T score of 40 is one SD better than average. However, for positively worded concepts like Physical Function Mobility, a T score of 60 is one SD better than average while a T score of 40 is one SD worse than average.

Time frame:
6 months
Reported as:
Mean · T-scores
Mean PROMIS-29 Scores at End of Treatment
T-scoresRadium Ra 223 Dichloride and Radiation, All Patients
Pain Interference53.5 ± 9.3
Depression/Sadness44.7 ± 6.1
Physical Function46.9 ± 11.2
Fatigue47 ± 10.1
Anxiety/Fear45.2 ± 6.6
Sleep Disturbance49.1 ± 7.7
Satisfaction with Social Roles and Activities49.8 ± 7.7
SecondaryEvaluate Time to First Skeletal Related Event (SRE)

Documentation of complications associated with bone metastases and may include (but not limited to) fractures, spinal cord compression, bone pain, and hypercalcemia.

Time frame:
2 years
Reported as:
Mean · Days
Evaluate Time to First Skeletal Related Event (SRE)
DaysRadium Ra 223 Dichloride and Radiation, All Patients
Evaluate Time to First Skeletal Related Event (SRE)554.5 ± 154.9
SecondaryEvaluate the PSA Doubling Time

This outcome measure will report the mean time elapsed from baseline PSA to PSA to double in value. Participants were followed for 24 months from the initiation of study treatment. PSA doubling time was censored at 24 months.

Time frame:
2 years, assessed at every visit in that time period
Reported as:
Mean · months
Evaluate the PSA Doubling Time
monthsRadium Ra 223 Dichloride and Radiation, All Patients
Evaluate the PSA Doubling Time19.32 ± 8.26
SecondaryEvaluate Overall Surival

This outcome measure will report the overall survival at 2 years. Patients were followed for survival for two years after study enrollment. Patients who refused follow-up were censored at their off-study date.

Time frame:
2 years after study enrollment
Reported as:
Mean · month
Evaluate Overall Surival
monthRadium Ra 223 Dichloride and Radiation, All Patients
Evaluate Overall Surival22.98 ± 4.55

Adverse events

Collected over The collection of all adverse events will begin after the first dose of study treatment and end 30 days after the last dose of study treatment. The collection of treatment-related adverse events will continue until the last study visit (or until new cancer treatment is initiated, if sooner).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Radium Ra 223 Dichloride and Radiation, All Patients0/20 (0%)1/20 (5%)20/20 (100%)
Most frequent serious events
Most frequent serious events
EventRadium Ra 223 Dichloride and Radiation, All Patients
Bone painMusculoskeletal and connective tissue disorders1/20
FractureInjury, poisoning and procedural complications1/20
Most frequent other events
Showing 10 of 46
Most frequent other events
EventRadium Ra 223 Dichloride and Radiation, All Patients
FatigueGeneral disorders14/20
NauseaGastrointestinal disorders5/20
Back painMusculoskeletal and connective tissue disorders4/20
Bone painMusculoskeletal and connective tissue disorders4/20
DiarrheaGastrointestinal disorders4/20
HematuriaRenal and urinary disorders3/20
Abdominal painGastrointestinal disorders2/20
Edema limbsGeneral disorders2/20
Respiratory, thoracic and mediastinal disorders - Other, specifyRespiratory, thoracic and mediastinal disorders2/20
Surgical and medical procedures - Other, specifySurgical and medical procedures2/20

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Radium Ra 223 Dichloride and Radiation, All Patients
<=18 years0
Between 18 and 65 years3
>=65 years17
Sex: Female, Male
Sex: Female, Male(Participants)Radium Ra 223 Dichloride and Radiation, All Patients
Female0
Male20
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Radium Ra 223 Dichloride and Radiation, All Patients
Hispanic or Latino0
Not Hispanic or Latino20
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Radium Ra 223 Dichloride and Radiation, All Patients
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White19
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Radium Ra 223 Dichloride and Radiation, All Patients
United States20
08

Study locations

1 site
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Sep 2022, 55 months.

Results were first posted in Jan 2024, 1 year 4 months after primary completion.

Of 612 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's 55 months is close to that.

Counting every sponsor, half of 726 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2017
First posted
Oct 9, 2017
StartActual
Feb 27, 2018
Primary completionActual
Sep 30, 2022
CompletionActual
Aug 31, 2023
Results first posted
Jan 30, 2024
Last update
Apr 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03304418
Lead sponsor
University of Utah
Collaborators
Bayer
Responsible party
Sponsor
First posted
Oct 9, 2017
Start date
Feb 27, 2018
Primary completion
Sep 30, 2022
Completion
Aug 31, 2023
Results posted
Jan 30, 2024
Last update
Apr 30, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Radium Ra 223 dichloride

Start the discussion